SPC
NTLA icon

Sigma Planning Corp’s Intellia Therapeutics NTLA Stock Holding History

Sigma Planning Corp’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$172K Buy
+10,141
New +$142K ﹤0.01% 1358
2025
Q3 		– Sell
-10,616
Closed -$99.6K – 1350
2025
Q2 		$99.6K Buy
+10,616
New +$87.2K ﹤0.01% 1208

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Sigma Planning Corp's NTLA Position: Q2 2026 in Review

Sigma Planning Corp opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 10,141 shares worth $172K. The stake represents ﹤0.01% of the portfolio and ranks #1358 among its holdings. This is a return to the name: Sigma Planning Corp previously reported a position in NTLA as recently as Q2 2025.

Sigma Planning Corp first reported a position in NTLA in Q2 2025 and has held it in 2 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Sigma Planning Corp held 10,141 shares of Intellia Therapeutics worth $172K as of Q2 2026.
  • Intellia Therapeutics was a new Sigma Planning Corp position in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Sigma Planning Corp's portfolio in Q2 2026, its #1358 holding.
  • Sigma Planning Corp first reported a position in Intellia Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Sigma Planning Corp's 13F filing for Q2 2026, filed 7 Aug 2026.